TAF (trade name: Veride?) is a nucleoside reverse transcriptase inhibitor and a prodrug of tenofovir. It becomes active after metabolism in the body and acts on liver cells to exert its effects. . Compared with TDF, TAF acts on liver cells more efficiently (less than 1/10 of the dose can have similar efficacy) and has fewer adverse reactions. Therefore, TAF is known as the "miracle drug for hepatitis B". It has been approved by the US FDA on November 10, 2016, the Japanese PMDA on December 19, 2016, and the European Union on January 9, 2017. EMA approved.
On December 8, 2018, Gilead Sciences announced that the chronic hepatitis B drug Veride? (tenofovir alafenamide fumarate tablets), which was approved in China on November 8, was officially launched. It is suitable for the treatment of chronic hepatitis B in adults and adolescents (over 12 years old, weighing 35kg and above). In the past ten years, Veride? is the only new hepatitis B drug approved by the FDA.
If you have questions about this answer, or have other questions about hepatitis B, you can download the vili Weiyou app, which can also help you manage checklists and conduct medication analysis!